These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 8234141)

  • 1. Therapeutic potential of cholecystokinin receptor antagonists in CNS disorders.
    Schiantarelli P
    Pharmacol Res; 1993; 28(1):1-9. PubMed ID: 8234141
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cholecystokinin antagonists: anxiolytic drugs of the future].
    Bourin M; Bradwejn J
    Pathol Biol (Paris); 1992 Mar; 40(3):215-7. PubMed ID: 1608663
    [No Abstract]   [Full Text] [Related]  

  • 3. The cholecystokinin receptor antagonist devazepide enhances morphine-induced analgesia but not morphine-induced respiratory depression in the squirrel monkey.
    Dourish CT; O'Neill MF; Schaffer LW; Siegl PK; Iversen SD
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1158-65. PubMed ID: 2262899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular modelling of asperlicin derived cholecystokinin A receptor antagonists.
    Van der Bent A; Ter Laak AM; IJzerman AP; Soudijn W
    Eur J Pharmacol; 1992 Aug; 226(4):327-34. PubMed ID: 1397061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area.
    Meltzer LT; Christoffersen CL; Serpa KA; Razmpour A
    Synapse; 1993 Feb; 13(2):117-22. PubMed ID: 8446920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cholecystokinin and its antagonists: effects on digestive motility].
    Bruley des Varannes S; Cloarec D; Dubois A; Galmiche JP
    Gastroenterol Clin Biol; 1991; 15(10):744-57. PubMed ID: 1816015
    [No Abstract]   [Full Text] [Related]  

  • 7. Differential effects of benzodiazepines, including diazepam, clonazepam, Ro 5-4864 and devazepide, on lindane-induced toxicity.
    Woolley DE
    Proc West Pharmacol Soc; 1994; 37():131-4. PubMed ID: 7527152
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
    Martín-Martínez M; Bartolomé-Nebreda JM; Gómez-Monterrey I; González-Muñiz R; García-López MT; Ballaz S; Barber A; Fortuño A; Del Río J; Herranz R
    J Med Chem; 1997 Oct; 40(21):3402-7. PubMed ID: 9341915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Receptor agonists and antagonists: the present and future].
    Tanaka H
    Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1813-26. PubMed ID: 8210427
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of CCK receptor antagonists on plasma CCK bioassay].
    Sun G; Pan GZ; Ma F; Wen SH; Du SF
    Sheng Li Xue Bao; 1992 Dec; 44(6):609-13. PubMed ID: 1302379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist.
    Wolkowitz OM; Gertz B; Weingartner H; Beccaria L; Thompson K; Liddle RA
    Biol Psychiatry; 1990 Jul; 28(2):169-73. PubMed ID: 2378921
    [No Abstract]   [Full Text] [Related]  

  • 12. Cholecystokinin receptors: synthetic antagonists with selectivity for receptor subtypes and possible clinical applications.
    Iversen LL; Dourish CT; Iversen SD
    Biochem Soc Trans; 1991 Nov; 19(4):913-5. PubMed ID: 1794582
    [No Abstract]   [Full Text] [Related]  

  • 13. Cholecystokinin receptor antagonists.
    Zucker KA; Adrian TE; Modlin IM
    J Surg Res; 1988 Nov; 45(5):496-504. PubMed ID: 3054325
    [No Abstract]   [Full Text] [Related]  

  • 14. CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons.
    Rasmussen K
    Ann N Y Acad Sci; 1994 Mar; 713():300-11. PubMed ID: 8185172
    [No Abstract]   [Full Text] [Related]  

  • 15. Ionic mechanisms underlying cholecystokinin action in rat brain.
    Boden P; Woodruff GN
    Ann N Y Acad Sci; 1994 Mar; 713():129-37. PubMed ID: 7910440
    [No Abstract]   [Full Text] [Related]  

  • 16. Cholecystokinin antagonists may have detrimental effects on acute pancreatitis.
    Dios ID; Manso MA
    Dig Dis Sci; 2006 Feb; 51(2):427-8. PubMed ID: 16534692
    [No Abstract]   [Full Text] [Related]  

  • 17. Brain cholecystokinin receptors and satiety.
    Nutr Rev; 1990 Sep; 48(9):359-60. PubMed ID: 2096338
    [No Abstract]   [Full Text] [Related]  

  • 18. Cholecystokinin receptors in relation to brain dopaminergic pathways.
    Woodruff GN
    Neurochem Int; 1992 Mar; 20 Suppl():339S-343S. PubMed ID: 1365453
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel cholecystokinin antagonists from Aspergillus alliaceus. II. Structure determination of asperlicins B, C, D, and E.
    Liesch JM; Hensens OD; Zink DL; Goetz MA
    J Antibiot (Tokyo); 1988 Jul; 41(7):878-81. PubMed ID: 3417562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel cholecystokinin antagonists from Aspergillus alliaceus. I. Fermentation, isolation, and biological properties.
    Goetz MA; Monaghan RL; Chang RS; Ondeyka J; Chen TB; Lotti VJ
    J Antibiot (Tokyo); 1988 Jul; 41(7):875-7. PubMed ID: 3417561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.